PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1419079
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1419079
Bispecific Antibody Therapeutics Contract Manufacturing Market size was valued at USD 5,289.1 Million in 2022, expanding at a CAGR of 36.23% from 2023 to 2030.
Therapeutics using bispecific antibodies Contract manufacturing is the practice of contracting out to specialist contract manufacturing organizations (CMOs) the manufacturing procedures involved in creating bispecific antibodies. Bispecific antibodies are a class of medicinal compounds designed to target two different antigens at the same time. These antigens are frequently found on the surface of cells that are linked to diseases such as infectious diseases, autoimmune disorders, and cancer.
During the forecast period, the market for contract manufacturing of bispecific antibody (bsAB) therapies is expected to grow primarily due to increased research and development efforts aimed at finding new therapeutics. The market has been seeing exponential expansion over the last few years, and this trend is expected to continue over the analysis period. The main reason for this is the strong pipeline of bispecific antibodies that will probably be introduced throughout the projection period. Moreover, a key driver of the market's profitable expansion is the expanding pipeline of anti-cancer treatments. For example, according to the U.S. FDA, more than 85% of bispecific antibodies in clinical trials are intended to treat cancer as of 2022.
Furthermore, as bispecific antibody therapies have such significant therapeutic potential in treating cancer and other disorders, there has been an increase in demand for them since the pandemic. Moreover, several bispecific antibodies are now in the early stages of clinical development. Therefore, in the upcoming years, it is anticipated that this aspect will positively affect market growth. Furthermore, there is a developing pipeline of bispecific antibody therapies, which is anticipated to boost market expansion opportunities.
The Global Bispecific Antibody Therapeutics Contract Manufacturing Market is segmented on the basis of Indication, Route of Administration, End-User, and Region.
The market is divided into five categories based on Indication: cancer, infectious diseases, autoinflammatory and autoimmune diseases, CNS Conditions, and others. The cancer segment dominates the market. Rapid developments in cancer effective therapies are boosting segment growth.
The market is divided into three categories based on Route of Administration: intravenous, subcutaneous, and others. The intravenous segment dominates the market and is likely to maintain its dominance during the forecast period. The growing adoption of the subcutaneous route of administration is likely to boost market growth.
The market is divided into three categories based on End-User: biopharmaceutical companies, research institutes, and others. The biopharmaceutical companies segment dominates the market and is likely to maintain its dominance during the forecast period. Increased need for new and improved drugs is boosting the therapeutics demand.
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
Bispecific antibody therapeutics contract manufacturing market is moderately competitive in nature. The major players in the market are engaged on the adoption of in-organic strategic initiatives, such as mergers & acquisitions, partnerships, and R&D activities. For example, the European Commission authorized the conditional marketing of bsAB Lunsumio (mosunetuzumab), a CD20xCD3 T-cell binding drug, in June 2022. It will be applied to patients with relapsed or resistant follicular lymphoma.
In March 2023, InvoX Pharma Limited reported that F-star, a subsidiary of InvoX, has agreed to collaborate with Takeda on an immuno-oncology bsAB.
The scope of this report covers the market by its major segments, which include as follows: